Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

ClinicalTrials.gov ID: NCT07578649

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07578649. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 8:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

AN INTERVENTIONAL PHASE 3, OPEN LABEL, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH ADVANCED OR RECURRENT MISMATCH REPAIR PROFICIENT ENDOMETRIAL CANCER

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is being conducted to assess whether the study medicine PF 08634404, given in combination with chemotherapy, improves outcomes compared with another medicine called pembrolizumab plus chemotherapy. Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. Our bodies have a built-in DNA "spell-checker," called the mismatch repair (MMR) system, that fixes genetic mistakes. In most endometrial cancers, this system works normally, and these cancers are called MMR-proficient (pMMR). However, pMMR tumors are harder for the immune system to recognize and attack. When endometrial cancer has spread beyond the uterus or comes back after previous treatment, it is called advanced or recurrent endometrial cancer. This study is for adults with mismatch repair-pMMR advanced or recurrent endometrial cancer. Participants must meet key criteria, including: * Women who are 18 years or older, and not pregnant at the time of joining the study * pMMR endometrial cancer only * Measurable Stage III disease, Stage IV disease (with or without measurable disease) per FIGO staging, a system doctors use to describe how far cancer has spread in the body, or recurrent (with or without measurable disease) endometrial cancer * Has not received chemotherapy except for chemotherapy given after the main surgery and more than 6 months before relapse * Be in good enough health to receive study treatment. Approximately 600 adult women will be enrolled. Each participant will be randomly assigned (like a flip of the coin) to one of two treatment groups, with about half in each group. The study is open, meaning both the doctors and participants know what treatment is being given. Participants will receive their assigned treatment through intravenous infusions (medicine is given directly into a vein). The treatment will be given in cycles. Experimental Group will receive new study medicine called PF-08634404 plus chemotherapy. It will be followed by PF 08634404 alone for up to 2 years (35 cycles). Control Group will receive an approved medicine called pembrolizumab plus chemotherapy. It will be followed by pembrolizumab alone for up to 2 years (20 cycles). The study will include regular visits for: * Participants will have regular visits to the study site for treatment, health checks, and tests. * After stopping treatment, participants will come for a final visit within a month to check their health and review any reactions. * Follow-up will continue every 12 weeks by phone or in person or by reviewing health records. This helps check health and any new treatments. * Tests will be done every 9 weeks during the first 104 weeks to see how the cancer is responding. After that, tests will be done every 12 weeks.

Study identification

NCT ID
NCT07578649
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
600 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 5, 2026 (Actual)
Primary completion
Sep 29, 2029 (Estimated)
Completion
Mar 2, 2031 (Estimated)
Last update posted
Nov 20, 2026

2026 – 2031

United States locations

U.S. sites
42
U.S. states
11
U.S. cities
34
Facility City State ZIP Site status
Jupiter Medical Center/ Anderson Family Cancer Institute Jupiter Florida 33458 Recruiting
Orlando Health Ambulatory Care Center Orlando Florida 32806 Recruiting
Orlando Health Cancer Institute Orlando Florida 32806 Recruiting
Orlando Health Orlando Regional Medical Center Orlando Florida 32806 Recruiting
Orlando Health Winnie Palmer Hospital for Women & Babies Orlando Florida 32806 Recruiting
Minnesota Oncology Hematology, PA Coon Rapids Minnesota 55433 Recruiting
Minnesota Oncology Hematology, PA Edina Minnesota 55435 Recruiting
Minnesota Oncology Hematology, PA Maple Grove Minnesota 55369 Recruiting
Minnesota Oncology Hematology, PA Maplewood Minnesota 55109 Recruiting
Minnesota Oncology Hematology, PA Woodbury Minnesota 55125 Recruiting
The Center of Hope Reno Nevada 89511 Recruiting
New York Oncology Hematology Albany New York 12206 Not yet recruiting
White Plains Hospital White Plains New York 10601 Recruiting
Miami Valley Hospital South Centerville Ohio 45459 Recruiting
Northwest Cancer Specialists, P.C. Happy Valley Oregon 97015 Recruiting
Northwest Cancer Specialists, P.C. Portland Oregon 97227 Recruiting
Northwest Cancer Specialists, P.C. Tigard Oregon 97223 Recruiting
Sarah Cannon Research Institute- Pharmacy Nashville Tennessee 37203 Recruiting
SCRI Oncology Partners Nashville Tennessee 37203 Recruiting
Texas Oncology - West Texas Abilene Texas 79606 Recruiting
Texas Oncology-West Texas Amarillo Texas 79124 Recruiting
Texas Oncology - Central South Austin Texas 78731 Recruiting
Texas Oncology - Central South Austin Texas 78745 Recruiting
Texas Oncology - Central South Austin Texas 78758 Recruiting
Texas Oncology-West Texas El Paso Texas 79902 Recruiting
Texas Oncology - West Texas El Paso Texas 79915 Recruiting
Texas Oncology - West Texas El Paso Texas 79938 Recruiting
Texas Oncology - Central South Harlingen Texas 78550 Recruiting
US Oncology Investigational Products Center (IPC) Irving Texas 75063 Recruiting
Texas Oncology - Central South McAllen Texas 78503 Recruiting
Texas Oncology-West Texas Midland Texas 79701 Recruiting
Texas Oncology - West Texas Odessa Texas 79761 Recruiting
Texas Oncology - Central South Waco Texas 76712 Recruiting
Texas Oncology - Central South Weslaco Texas 78596 Recruiting
Texas Oncology-West Texas Wichita Falls Texas 76310 Recruiting
Virginia Oncology Associates Chesapeake Virginia 23320 Recruiting
Virginia Oncology Associates Newport News Virginia 23606 Recruiting
Virginia Oncology Associates Norfolk Virginia 23502 Recruiting
Virginia Oncology Associates Suffolk Virginia 23435 Recruiting
Virginia Oncology Associates Williamsburg Virginia 23188 Recruiting
Northwest Cancer Specialists, P.C. Vancouver Washington 98684 Recruiting
Minnesota Oncology Hematology, P.A. Hudson Wisconsin 54016 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07578649, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 20, 2026 · Synced Nov 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.